LYNX1 and neoplasm: This observation suggests that these neuropeptide genes are dysregulated during tumor initiation to modulate the neuroimmune axis, ultimately paving the way for tumor formation; LYNX1 could have a protective role, and its expression decreased as the tumor progressed from Stage I to Stage IV.